Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...

Researchers at the University of Arizona have uncovered a previously unknown population of circulating immune cells that play ...

MHH researchers introduce mRNA with a building block for telomerase into human lung cells to reduce ageing processes and fibrosis development. The original paper, ‘Telomerase modRNA Offers a Novel RNA ...

BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders and autoimmune therapeutics, today ...

Researchers at the University of Arizona say a previously unknown population of circulating immune cells play a critical role ...

Researchers discover circulating immune cells that drive fibrosis, revealing a new therapeutic target to prevent scar tissue ...

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced that it has submitted ...

With air pollution surging to dangerous levels in the national capital, doctors are raising red flags about its serious impact on chronic lung diseases, especially Chronic Obstructive Pulmonary ...

Her resilience and openness helped spark wider conversations about this often misunderstood condition. To better understand IPF, we reached out to Dr Sunil Kumar K, Lead Consultant – Interventional ...